Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods

Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet